Investigational Drug Information for Basimglurant
✉ Email this page to a colleague
What is the development status for investigational drug Basimglurant?
Basimglurant is an investigational drug.
There have been 3 clinical trials for Basimglurant.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 11th 2022.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Trigeminal Neuralgia. The leading clinical trial sponsors are Noema Pharma AG, Hoffmann-La Roche, and [disabled in preview].
Summary for Basimglurant
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 31 |
| WIPO Patent Applications | 16 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 1 (2022-01-11) |
| Vendors | 0 |
Recent Clinical Trials for Basimglurant
| Title | Sponsor | Phase |
|---|---|---|
| An Efficacy and Safety Study of Basimglurant in Patients With Trigeminal Neuralgia. | Noema Pharma AG | Phase 2/Phase 3 |
| Basimglurant in Children and Adolescents With TSC | Noema Pharma AG | Phase 2 |
| A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD) | Hoffmann-La Roche | Phase 1 |
Clinical Trial Summary for Basimglurant
Top disease conditions for Basimglurant
Top clinical trial sponsors for Basimglurant
US Patents for Basimglurant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
